Congratulations to Allinaire, whose novel therapeutics for pulmonary diseases are based on research by Dr. Matthias Clauss of the Indiana University School of Medicine!
Allinaire recently received new investments from BioCrossroads’ Indiana Seed Fund II; BioMotiv, a biomedical accelerator affiliated with the Harrington Project for Discovery & Development; and the Innovate Indiana Fund to advance the development of therapeutics for the treatment of AAT deficiency, Chronic Obstructive Pulmonary Disorder, and other respiratory disorders, including acute lung injury. In addition, the company has received grant support from the National Institutes of Health, Small Business Innovation & Research program.
“Allinaire Therapeutics’ technology demonstrates great potential to become a disease-modifying approach to COPD and emphysema. As Class A investors, Innovate Indiana looks forward to working closely with the Allinaire Therapeutics team to ensure the continued success of the technology and the company,” said Ken Green, M.D., managing director of the Innovate Indiana Fund.
A news release is available here.
Congratulations Allinaire, another example of Indiana University research and innovation that is impacting people’s lives!
Leave a Reply